The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nanochemo-immunotherapy of ER-positive metastatic breast cancer (MBC) with PEG-liposomal doxorubicin (PLD) and pembrolizumab (PEM).
 
Alberto Gabizon
Stock and Other Ownership Interests - Johnson & Johnson/Janssen; Merck; Novo Nordisk
Honoraria - InnoMedica; LipoMedix
Consulting or Advisory Role - InnoMedica; LipoMedix
Research Funding - Merck
Patents, Royalties, Other Intellectual Property - INVENTOR OF PATENTS ASSIGNED TO LIPOMEDIX, INNOMEDICA, and SHAARE ZEDEK SCIENTIFIC. I HAVE NOT RECEIVED ROTALTIES IN LAST 2 YEARS
Travel, Accommodations, Expenses - InnoMedica
 
Ora Rosengarten
No Relationships to Disclose
 
Nathan Cherny
No Relationships to Disclose
 
Rut Isacson
No Relationships to Disclose
 
Areen Abu Remilah
No Relationships to Disclose
 
Shani Breuer
No Relationships to Disclose
 
Hadar Goldvaser
No Relationships to Disclose
 
Hilary Shmeeda
No Relationships to Disclose
 
Eli Golomb
No Relationships to Disclose
 
Yonatan Turner
No Relationships to Disclose
 
Albert Grinshpun
Honoraria - AstraZeneca; Novartis; Pfizer; Stemline Therapeutics
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Pfizer